MedPath

Salsalate

Generic Name
Salsalate
Drug Type
Small Molecule
Chemical Formula
C14H10O5
CAS Number
552-94-3
Unique Ingredient Identifier
V9MO595C9I

Overview

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Background

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Indication

For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.

Associated Conditions

No associated conditions information available.

FDA Approved Products

Salsalate
Manufacturer:ECI Pharmaceuticals LLC
Route:ORAL
Strength:750 mg in 1 1
Approved: 2022/08/26
NDC:51293-616
Salsalate
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:500 mg in 1 1
Approved: 2020/08/10
NDC:63629-9248
Salsalate
Manufacturer:Proficient Rx LP
Route:ORAL
Strength:750 mg in 1 1
Approved: 2022/11/01
NDC:71205-983
Salsalate
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:750 mg in 1 1
Approved: 2023/05/16
NDC:72162-1569
Salsalate
Manufacturer:ECI Pharmaceuticals LLC
Route:ORAL
Strength:500 mg in 1 1
Approved: 2022/08/26
NDC:51293-615

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath